Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- GE Healthcare
- Novo Nordisk
- AstraZeneca
- Takeda Pharmaceuticals U.S.A.
- MedImmune
- GlaxoSmithKline
- Janssen Pharmaceutica
- Merck
- Abbott Vascular
- Daiichi-Sankyo
- St. Jude Medical
- Eisai
- Abbott Laboratories
- Amgen
- Sanofi
- Bayer Fund
- Medtronic
- Zora Biosciences
- Janssen Research and Development
- Bayer HealthCare
- Forest Laboratories
- Eli Lilly and Company
- i2o Therapeutics
- Roche
- Medicines Company
- Novartis
This publication has 50 references indexed in Scilit:
- Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialThe Lancet, 2012
- Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary StentingCirculation, 2012
- Antiplatelet DrugsChest, 2012
- American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular DeathCirculation, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting StentsNew England Journal of Medicine, 2010
- Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary InterventionJACC, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA TrialJACC, 2007
- Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent PlacementCirculation, 2006